PT  - JOURNAL ARTICLE
AU  - Diana Avetyan
AU  - Andranik Chavushyan
AU  - Hovsep Ghazaryan
AU  - Ani Melkonyan
AU  - Ani Stepanyan
AU  - Roksana Zakharyan
AU  - Varduhi Hayrapetyan
AU  - Sofi Atshemyan
AU  - Gevorg Martirosyan
AU  - Gayane Melik-Andreasyan
AU  - Shushan Sargsyan
AU  - Armine Ghazazyan
AU  - Naira Aleksanyan
AU  - Xiushan Yin
AU  - Arsen Arakelyan
TI  - SARS-CoV-2 detection by extraction-free qRT-PCR for massive and rapid COVID-19 diagnosis during a pandemic
AID  - 10.1101/2020.09.10.20191189
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.10.20191189
4099  - http://medrxiv.org/content/early/2020/09/12/2020.09.10.20191189.short
4100  - http://medrxiv.org/content/early/2020/09/12/2020.09.10.20191189.full
AB  - COVID-19 pandemic severely impacted the healthcare and economy on a global scale. It is widely recognized that mass testing is an efficient way to contain the infection spread as well as the development of informed policies for disease management. However, the current COVID-19 worldwide infection rates increased demand in the rapid and reliable screening of SARS-CoV-2 infection.We compared the performance of qRT-PCR in direct heat-inactivated, heat-inactivated/pelleted samples against RNA in a group of 74 subjects (44 positive and 30 negative). In addition, we compared the sensitivity of heat-inactivated/pelleted in another group of 196 COVID-19 positive samples.Our study suggests that swab sample heat-inactivation and pelleting show higher accuracy for SARS-CoV-2 detection PCR assay compared to heat-inactivation only (89% vs 83% of the detection in RNA). The accuracy of detection using direct samples varied depending on the sample transport and storage media as well as the concentration of viral particles.Our study suggests that purified RNA provides more accurate results, however, direct qRT-PCR may help to significantly increase testing capacity. Switching to the direct sample testing is justified if the number of tests is doubled at least.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board of the Institute of Molecular Biology NAS RA (IRB#: 00004079).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A